Pathology: es-BC - HER2 positive - (neo)adjuvant (NA); la/mBC - HER2 positive - 1st Line (L1); la/mBC - HER2 positive - 2nd Line (L2);
es-BC - HER2 positive - (neo)adjuvant (NA) | la/mBC - HER2 positive - 1st Line (L1) | la/mBC - HER2 positive - 2nd Line (L2) | ||||||||||||
GeparQuinto, 2012 | PERTAIN, 2018 | CLEOPATRA, 2012 | PUFFIN, 2020 | SYSUCC-002, 2022 | LUX-Breast 1, 2016 | WJOG6110B/ELTOP, 2018 | EGF104900, 2010 | ExteNET, 2016 | NALA (brain metastases), 2020 | NALA, 2020 | HER2CLIMB (patients with brain metastases), 2020 | HER2CLIMB, 2020 | ||
neratinib plus capecitabine | 2 | T1 | T1 | |||||||||||
tucatinib plus trastuzumab plus capecitabine | 2 | T1 | T1 | |||||||||||
pertuzumab plus trastuzumab plus docetaxel | 2 | T1 | T1 | |||||||||||
trastuzumab plus endocrine therapy | 1 | T1 | ||||||||||||
lapatinib plus capecitabine | 1 | T1 | T0 | T0 | ||||||||||
pertuzumab plus trastuzumab | 1 | T1 | ||||||||||||
afatinib plus vinorelbine | 1 | T1 | ||||||||||||
neratinib | 1 | T1 | ||||||||||||
trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel | 1 | T1 | ||||||||||||
lapatinib plus trastuzumab | 1 | T1 | ||||||||||||
trastuzumab plus chemotherapy | 0 | T0 | ||||||||||||
trastuzumab plus capecitabine | 0 | T0 | T0 | T0 | ||||||||||
trastuzumab | 0 | T0 | ||||||||||||
trastuzumab plus docetaxel | 0 | T0 | T0 | |||||||||||
trastuzumab plus vinorelbine | 0 | T0 | ||||||||||||
placebo | 0 | T0 | ||||||||||||
lapatinib plus epirubicin and cyclophosphamide followed by docetaxel | 0 | T0 | ||||||||||||
lapatinib | 0 | T0 |